ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. October 15, 2019
ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 18, 2019
ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 08, 2021
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Press release … rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique … April 23, 2021
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 05, 2021
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Press release Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally October 05, 2020
ProQR Announces Virtual Presentations at Scientific Conferences Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. September 24, 2020
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Press release Extends ProQR’s cash runway into 2023ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass. , July 14, 2020 (GLOBE NEWSWIRE) -- July 14, 2020
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. October 07, 2019
